Cargando…
Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination
This letter to the editor comments on a recently published article on seroconversion rates after COVID-19 vaccination.
Autores principales: | Sriwijitalai, Won, Wiwanitkit, Viroj |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9632302/ https://www.ncbi.nlm.nih.gov/pubmed/36018054 http://dx.doi.org/10.1093/oncolo/oyac169 |
Ejemplares similares
-
Esophagitis and SARS-CoV-2 vaccine
por: Sriwijitalai, Won, et al.
Publicado: (2023) -
Esophagitis and SARS-CoV-2 vaccine: Correspondence
por: Sriwijitalai, Won, et al.
Publicado: (2023) -
Seroconversion after Inactive SARS-CoV-2 Vaccination and Obesity: Correspondence
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2022) -
Relapse of minimal change disease and inactivated SARS-CoV-2 vaccination
por: Sriwijitalai, Won, et al.
Publicado: (2022) -
Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: correspondence
por: Mungmunpuntipanjtip, Rujittika, et al.
Publicado: (2022)